Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with imatinib-resistant myeloblastic-phase chronic myeloid leukaemia

Leukemia

Volumn 23, Issue 6, 2009, Pages 1158-1159

  Rea, D ^a   Raffoux, E ^a   Cayuela, J M ^b   Maarek, O ^b   Dombret, H ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b Laboratoire Central d'Hematologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BCR ABL PROTEIN; BUSULFAN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IMATINIB; PROTEIN TYROSINE KINASE;

ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLAST CELL CRISIS; CANCER GROWTH; CASE REPORT; CD34 SELECTION; CHRONIC MYELOID LEUKEMIA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL SYMPTOM; GENE REARRANGEMENT; GENE SEQUENCE; HLA MATCHING; HUMAN; KARYOTYPE 46,XY; KARYOTYPING; LEUKAPHERESIS; LEUKEMIA RELAPSE; MALE; METAPHASE CHROMOSOME; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUTATION; MUTATIONAL ANALYSIS; MYELOID LEUKEMIA; PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL MOBILIZATION; TREATMENT RESPONSE;

EID: 67349251483     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.376     Document Type: Article

References (4)

1. Brave M, Goodman V, Kaminskas E, Farrell A, Timmer W, Pope S et al Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008; 14: 352-359.
2. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58-60.
3. Weisberg E, Manley PW, Brettenstein W, Brüggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of wild type and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141.
4. Gabriel I, Chaidos A, Sorouri J, Dannie E, Davis J, Goldman J et al Successful peripheral stem cell mobilization with granulocyte colony-stimulating factor in a patient with chronic myeloid leukemia achieving a complete cytogenetic remission with dasatinib after failing imatinib. Leukemia 2008; 22: 1618-1619.